One-step prepared nano-in-micro microcapsule delivery vehicle with sequential burst–sustained drug release for the targeted treatment of inflammatory bowel disease
| Autor: | Jinyi Wang, Jingjing Jiang, Jingcheng Xiao, Mao-Sen Yuan, Zexu Zhao |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Drug
media_common.quotation_subject medicine.medical_treatment Inflammation 02 engineering and technology Pharmacology 010402 general chemistry 021001 nanoscience & nanotechnology medicine.disease 01 natural sciences Inflammatory bowel disease 0104 chemical sciences Proinflammatory cytokine Targeted therapy PLGA chemistry.chemical_compound chemistry Pharmacokinetics Targeted drug delivery Materials Chemistry medicine General Materials Science medicine.symptom 0210 nano-technology media_common |
| Zdroj: | Materials Chemistry Frontiers. 5:6027-6040 |
| ISSN: | 2052-1537 |
| Popis: | Orally targeted drug delivery for treating colonic diseases has attracted much attention because this method can be used as a better alternative to conventional administration of high drug doses, which usually exposes patients to serious systemic toxicity. Here, a pH-responsive nano-in-micro composite as a drug-delivery vehicle for the targeted therapy of inflammatory bowel disease (IBD) is designed and prepared using a one-step droplet microfluidic method with a water-in-oil-in-water manner. The microcapsules, encapsulating both free drugs and drug-loaded nanoparticles (NPs), appear as bowl-shaped spheres with a non-uniform shell thickness. Under colonic pH, the thin concave lamella of the HPMCAS-based shells rapidly ruptures and releases the inner free drug to achieve burst drug release for a sufficiently high and effective concentration of the drug. Subsequently, the gradual decomposition of PLGA-based drug-loaded NPs results in sustained drug release. The sequential burst–sustained drug release is consistent with the pharmacokinetics and medication needs of IBD. In vitro inflammation inhibition experiments further reveal that the nano-in-micro microcapsules can quickly alleviate the inflammatory response at the site of inflammation by reducing the intracellular ROS level and the expression of proinflammatory cytokines. These results demonstrate the success of the targeted drug-delivery model with the function of sequential burst–sustained drug release for IBD therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|